Russia's National Wealth Fund will supply 100 million doses of its coronavirus vaccine, Sputnik-V, to Indian drug company Dr. Reddy's Laboratories, according to the fund. 

New Delhi.- The Russian National Wealth Fund (NWF) and the Indian company agreed to cooperate with phase-III clinical trials and distribution of the coronavirus vaccine Sputnik-V across the South Asian country, according to the Down to Earth portal.

The Sputnik-V vaccine was subjected to phase-1 and -2 trials, and results were published in The Lancet specialized journal.

Sputnik V, based on an adenovirus vector, was developed by Gamaleya Scientific Research Institute of Epidemiology and Microbiology, together with NWF, and registered on August 11, the source added.

The supply could begin in late 2020 as long as trials are completed successfully and the regulatory authorities in India register the new vaccine.

Meanwhile, Balram Bhargava, director-general of the Indian Council for Medical Research, praised Russia's record in manufacturing vaccines. (PL)